Breast Cancer
Carrick Therapeutics Advances Second CDK Inhibitor Into Clinic, Explores Biomarker Approaches
Premium
The Boston-based firm just launched the first trial of a CDK12/13 inhibitor and is anticipating starting Phase III trials for a CDK7 inhibitor in 2026.
UK Consortium Launches With Public-Private Funding to ID Immunotherapy Biomarkers
The Francis Crick Institute and the Royal Marsden Foundation Trust are spearheading the MANIFEST project with £21.9 million in government and industry funding.
The company is targeting its RPPA-based testing to biopharma firms as well as for clinical trial work and to clinicians to help guide therapy in cancer patients.
Owkin, AstraZeneca Partner to Develop AI-Based Breast Cancer Prescreening Tool
The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.
AstraZeneca, Daiichi Sankyo's Enhertu BLA in HER2-Low, Ultralow Breast Cancer Gets FDA Priority Review
The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.